share_log

Beyond The Numbers: 7 Analysts Discuss Silence Therapeutics Stock

Beyond The Numbers: 7 Analysts Discuss Silence Therapeutics Stock

超越數字:7位分析師討論Silence Therapeutics股票
Benzinga ·  04/22 14:00
7 analysts have expressed a variety of opinions on Silence Therapeutics (NASDAQ:SLN) over the past quarter, offering a diverse set of opinions from bullish to bearish.
在過去的一個季度中,有7位分析師對Silence Therapeutics(納斯達克股票代碼:SLN)表達了各種各樣的觀點,從看漲到看跌。
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
下表總結了他們最近的評級,展示了過去30天內不斷變化的情緒,並將其與前幾個月進行了比較。
Analysts have set 12-month price targets for Silence Therapeutics, revealing an average target of $60.57, a high estimate of $75.00, and a low estimate of $42.00. This current average reflects an increase of 38.45% from the previous average price target of $43.75.
分析師已經爲Silence Therapeutics設定了12個月的目標股價,顯示平均目標股價爲60.57美元,最高估計爲75.00美元,低估值爲42.00美元。目前的平均價格比之前的平均目標價43.75美元上漲了38.45%。
Decoding Analyst Ratings: A Detailed Look
解碼分析師評級:詳細介紹
The analysis of recent analyst actions sheds light on...
對分析師最近行爲的...
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論